



Dear Investor,

This letter provides a brief overview of the 2025 financial year and outlines some of the core tenets of the Fund's investment philosophy. A more detailed commentary, including individual stock and attribution analysis, will be included in our June 2025 Quarterly Commentary, to be released later this month.

The Fund enjoyed a solid year of performance in FY25, in what has been a noisy backdrop in global equity markets. While the year was certainly eventful, macroeconomic and geopolitical uncertainty is nothing new. In fact, we find that most years present transitory reasons to feel either euphoric or anxious about equity markets. This year's most striking example was the 'Liberation Day' tariff announcement in April, which triggered one of the sharpest declines in global equity markets on record. The S&P 500 fell 12% in just four trading days, while the S&P/ ASX 200 declined 7%. Yet, despite the initial shock and lingering threat of tariffs, markets have guickly recovered to above pre-tariff levels. The lesson, time and time again, is that attempting to predict and time markets is a fool's errand. We instead focus our efforts on what we believe we can predict - namely, the long-term economics of high-quality, durable businesses.

Among the Fund's strongest contributors during FY25 were Sigma Healthcare, Nick Scali, Gentrack, and News Corp. We have extolled the virtues of each of these businesses in various quarterly commentaries over the past two years, which can be found on the Airlie website. On the other side of the ledger, Tabcorp and Smartpay were two material detractors during FY25, which we have also written about extensively in past commentaries. While our position in Tabcorp has been reduced substantially, we remain confident in our Smartpay holding, with multiple bidders emerging for the company over the past few months.

It is worth noting that many of the top-performing holdings in FY25 were also among last year's leaders. This is a feature, not a bug, of our investment philosophy. We believe the most reliable path to wealth creation in equities is to buy quality businesses at attractive prices, hold them for the long term and allow them to compound over time. We do our best to avoid interrupting that process unnecessarily, which is why our top holdings are unlikely to change too materially from one year to another. Of course, defining what constitutes a 'quality' business can be subjective. For us, it refers to companies with durable competitive advantages that are protected from competition and can grow at attractive rates on incremental capital. The durability of a business model is particularly important, as long-dated cash flows underwrite a substantial portion of intrinsic value. We therefore concentrate on businesses where we can reasonably predict their economics several years into the future, often avoiding sectors prone to frequent disruption.



Source: Airlie



Our goal each year is to enhance the portfolio by selectively adding high-quality compounders at attractive valuations. This is an inherently difficult task – the market is usually very efficient at identifying these businesses and pricing them accordingly. Nevertheless, in FY25 we did make some progress in a few names. Most notably, we materially upweighted our position in Sigma Healthcare, which has recently merged with Chemist Warehouse. Chemist Warehouse exemplifies everything we look for in a business - an impregnable economic moat, fantastic founder-led management team, fortress balance sheet, and decades of runway to deploy capital within the business's core competency. Fortuitously for us, the nature of the merger gave us the opportunity to purchase this remarkable business at a price we deemed very attractive. Hopefully FY₂6 throws up further opportunities to add great businesses like Chemist Warehouse to the Fund.

Looking ahead, we remain optimistic about the Fund's prospects. We own a concentrated portfolio of competitively advantaged businesses with long runways to deploy capital – many of which we believe are materially undervalued. The small cap universe is rich with mispriced securities: with over 700 stocks within our remit, we are focused on identifying just 20 - 40 compelling opportunities. I have a substantial personal investment in the Fund, and my commitment to preserving and growing your wealth, alongside my own, remains steadfast.

Thank you for your continued support.

Will Granger Portfolio Manager

To find out more about the Airlie Small Companies Fund, please contact us on:

E: adviserservices@airliefm.com.au P: +61 2 9235 4760 W: airliefundsmanagement.com.au

IMPORTANT INFORMATION: Units in the fund(s) referred to herein are issued by Magellan Asset Management Limited (ABN 31 120 593 946, AFS Licence No. 304 301) trading as Airlie Funds Management ('Airlie'). This material is issued by Airlie and has been prepared for general information purposes only and must not be construed as investment advice or as an investment recommendation. This material does not take into account your investment objectives, financial situation or particular needs. This material does not constitute an offer or inducement to engage in an investment activity nor does it form part of any offer documentation, offer or invitation to purchase, sell or subscribe for interests in any type of investment product or service. You should obtain and consider the relevant Product Disclosur Statement ('PDS') and Target Market Determination ('TMD') and consider obtaining professional investment advice tailored to your specific circumstances before making a decision to acquire, or continue to hold, the relevant financial product. A copy of the relevant PDS and TMD relating to an Airlie financial product or service may be obtained by calling +61 2 9235 4760 or by visiting www.airliefundsmanagement.com.au.

Past performance is not necessarily indicative of future results and no person guarantees the future performance of any fund, the amount or timing of any return from it, that asset allocations will be met, that it will be able to implement its investment strategy or that its investment objectives will be achieved. Statements contained in this material that are not historical facts are based on current expectations, estimates, projections, opinions and beliefs of Airlie or the third party responsible for making those statements (as relevant). Such statements involve known and unknown risks, uncertainties and other factors, and undue reliance should not be placed thereon. This material may contain 'forward-looking statements'. Actual events or results or the actual performance of an Airlie financial product or service may differ materially from those reflected or contemplated in such forward-looking statements. This material may include data, research and other information from third party sources. Airlie maks no guarantee that such information is accurate, complete or timely and does not provide any warranties regarding results obtained from its use. This information is subject to change at any time and no person has any responsibility to update any of the information provided in this material. No representation or warranty is made with respect to the accuracy or completeness of any of the information contained in this material. Airlie will not be responsible or liable for any losses arising from your use or reliance upon any part of the information contained in this material.

Further information regarding any benchmark referred to herein can be found at <u>www.airliefundsmanagement.com.au/benchmark-information/</u>. Any third-party trademarks contained herein are the property of their respective owners and Airlie claims no ownership in, nor any affiliation with, such trademarks. Any third-party trademarks that appear in this material are used for information purposes and only to identify the company names or brands of their respective owners. No affiliation, sponsorship or endorsement should be inferred from the use of these trademarks. This material and the information contained within it may not be reproduced, or disclosed, in whole or in part, without the prior written consent of Airlie. (300425-#A9) UID001